Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Does detection of microsatellite instability-high (MSI-H) by plasma-based testing predict tumor response to immunotherapy (IO) in patients with pancreatic cancer (PC)?
Authors
Sakti Chakrabarti
Mayo Clinic, Rochester, MN
Sakti Chakrabarti , Leslie A. Bucheit , Jason S. Starr , Racquel Innis-Shelton , Ardaman Shergill , Regina Resta , Stephanie Ann Wagner , Pashtoon Murtaza Kasi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.607
Abstract #
607
Poster Bd #
L3
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).
First Author: Takayuki Yoshino
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinical characteristics and the course of hepatobiliary and pancreatic malignant tumors with high microsatellite instability after pembrolizumab administration: A multicenter observational study.
First Author: Yuta Maruki
Poster
2020 Gastrointestinal Cancers Symposium
Impact of antibiotic exposure on the efficacy of immune checkpoint blockade in MSI-H metastatic CRC.
First Author: Victoria Serpas
Poster
2024 ASCO Genitourinary Cancers Symposium
Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.
First Author: Daniel M. Geynisman